Eftychia Lekka

Eftychia Lekka

Auto-generated profile, based on publicly available information

Eftychia Lekka

Biovista, Athens, Greece

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MSMaria Salagianni
Maria Salagianni
ELEftychia Lekka
Eftychia Lekka
AMArdiana Moustaki
Ardiana Moustaki
EIEleni G. Iliopoulou
Eleni G. Iliopoulou
CBConstantin N. Baxevanis
Constantin N. Baxevanis
SPSonia Perez
Sonia Perez
Previous work from our laboratory showed that hydrocortisone (HC) combined with IL-15 induces expansion of activated human NK cells. We set up an experimental tumor model to evaluate the use of adoptively transferred, HC plus IL-15 (HC/IL-15)–activated and –expanded murine NK cells in the treatment of syngeneic mice carrying established lung metastases of the CT26 transplantable tumor. We also examined the effect of denileukin diftitox (Ontak) on the depletion of regulatory T cells to enhance the in vivo antitumor immunity induced by the adoptively transferred NK cells. Our results clearly demonstrate that murine DX5+ NK cells are largely expanded in the presence of IL-15 plus HC while retaining intact their functional status. Moreover, when intravenously infused, they mediated significant antitumor responses against CT26 lung tumors in syngeneic BALB/c animals that were further enhanced upon pretreatment of the tumor-bearing animals with Ontak. Total splenocytes and isolated splenic T cells from NK-treated mice responded in vitro against CT26 tumor cells as evidenced by IFN-γ–based ELISPOT, proliferation, and cytotoxicity assays. Importantly, animals treated with Ontak plus adoptive transfer of HC/IL-15–expanded NK cells significantly retarded CT26 tumor growth after a rechallenge with the same tumor s.c. in their flanks. Taken altogether, our data suggest that NK cell adoptive transfer can trigger adaptive antitumor T cell responses, and regulatory T cell depletion by Ontak is mandatory for enabling HC/IL-15–activated NK cells to promote long-lasting adaptive antitumor immunity.

1 July 2008 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AGAngelos D. Gritzapis
Angelos D. Gritzapis
IVIoannis F. Voutsas
Ioannis F. Voutsas
ELEftychia Lekka
Eftychia Lekka
NTNikolaos Tsavaris
Nikolaos Tsavaris
IMIoannis Missitzis
Ioannis Missitzis
CBConstantin N. Baxevanis
Constantin N. Baxevanis
HER-2/neu oncoprotein is overexpressed in a variety of human tumors and is associated with aggressive disease. Immunogenic HER-2/neu CTL epitopes have been used as vaccines for the treatment of HER-2/neu positive malignancies with limited success. By applying prediction algorithms for MHC class I ligands and proteosomal cleavages, in this study, we describe the identification of HER-2/neu decamer LIAHNQVRQV spanning residues 85–94 (HER-2(1085)). HER-2(1085) proved to bind with high affinity to HLA-A2.1 and was stable for 4 h in an off-kinetics assay. This peptide was immunogenic in HLA-A2.1 transgenic (HHD) mice inducing peptide-specific CTL, which responded to tumor cell lines of various origin coexpressing human HER-2/neu and HLA-A2.1. This demonstrates that HER-2(1085) is naturally processed from endogenous HER-2/neu. Five of sixteen HER-2/neu+ HLA-A2.1+ breast cancer patients analyzed had HER-2(1085)-reactive T cells ranging from 0.35–0.70% of CD8+ T cells. Depletion of T regulatory cells from PBMC enabled the rapid expansion of HLA-A2.1/HER-2(1085)pentamer+/CD8+ cells (PENT+/CD8+), whereas significantly lower numbers of CTL could be generated from unfractionated PBMC. HER-2(1085)-specific human CTL recognized the HER-2/neu+ HLA-A2.1+ tumor cell line SKBR3.A2, as determined by IFN-γ intracellular staining and in the high sensitivity CD107α degranulation assay. Finally, HER-2(1085) significantly prolonged the survival of HHD mice inoculated with the transplantable ALC.A2.1.HER tumor both in prophylactic and therapeutic settings. These data demonstrate that HER-2(1085) is an immunogenic peptide, capable of eliciting CD8-mediated responses in vitro and in vivo, providing the platform for further exploitation of HER-2(1085) as a possible target for anticancer immunotherapy.

31 March 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
AGAngelos D. Gritzapis
Angelos D. Gritzapis
IVIoannis F. Voutsas
Ioannis F. Voutsas
ELEftychia Lekka
Eftychia Lekka
MPMichael Papamichail
Michael Papamichail
CBConstantin N. Baxevanis
Constantin N. Baxevanis
BALB/c mice transgenic (Tg) for the transforming rat neu oncogene (BALB-neuT) are genetically predestined to develop mammary carcinogenesis in a process similar to that in humans. We crossed HLA-A2.1/HLA-DR1 (A2.1/DR1) Tg mice with BALB-neuT mice to generate A2.1/DR1 × BALB-neuT triple Tg (A2.1/DR1 × neuT+) mice, which represent an improvement over BALB-neuT mice for evaluating vaccination regimens to overcome tolerance against HER-2/neu. A vaccine formulation strategy, consisting of synthetic peptides from the rat HER-2/neu oncogene combined with granulocyte macrophage colony-stimulating factor, was highly effective in preventing the growth of established transplantable tumors in male A2.1/DR1 × neuT+ mice. Vaccination with HER-2(435–443) (p435) CTL peptide alone induced weak antitumor responses, which were characterized by increased numbers of regulatory T cells (Treg) and low numbers of vaccine-specific CD8+ CTL and helper T cells (Th). The administration of p435 plus HER-2(776–790) (p776; helper peptide) reversed this situation, inducing functionally active, peptide-specific CTL and Th. There was a striking change in the intratumoral balance of Tregs (decrease) and vaccine-specific Th (increase) that directly correlated with tumor rejection. Intratumoral administration of anti-FasL antibody promoted tumor growth. The decrease in Tregs (Fas+) was due to apoptosis induced by cell contact with Fas ligand+ (L)+ Th. Mice vaccinated with p435 plus p776 exhibited long-lasting antitumor immunity. Our vaccine regimen also significantly delayed the outgrowth of mammary carcinomas in female A2.1/DR1 × neuT+ animals. We provide a mechanism to overcome tolerance against HER-2/neu, which proposes a combined vaccination with two (Th and CTL) HER-2 peptides against HER-2/neu–expressing tumors. Cancer Res; 70(7); 2686–96

1 March 2019 in Pharmacological Research
Verified
Journal Article
Closed access
SMStefano Manzini
Stefano Manzini
MBMarco Busnelli
Marco Busnelli
CPCinzia Parolini
Cinzia Parolini
LMLucia Minoli
Lucia Minoli
AOAlice Ossoli
Alice Ossoli
GCGiulia Chiesa
Giulia Chiesa

5 June 2020 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
CAChristos Andronis
Christos Andronis
João Pedro SilvaJoão Pedro Silva
João Pedro Silva
ELEftychia Lekka
Eftychia Lekka
VVVassilis Virvilis
Vassilis Virvilis
HCHelena Carmo
Helena Carmo
MSMiroslav Savić
Miroslav Savić
Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and elucidate potential biological mechanisms of action frequently associated with MCAEs, we present a unique workflow linking observational population data with the available knowledge at molecular, cellular, and psychopharmacology levels. It is based on statistical analysis of pharmacovigilance reports and subsequent signaling pathway analyses, followed by evidence-based expert manual curation of the outcomes. Our analysis: (a) ranked pharmaceuticals with high occurrence of such adverse events (AEs), based on disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database, and (b) identified 120 associated genes and common pathway nodes possibly underlying MCAEs. Nearly two-thirds of the identified genes were related to immune modulation, which supports the critical involvement of immune cells and their responses in the regulation of the central nervous system function. This finding also means that pharmaceuticals with a negligible central nervous system exposure may induce MCAEs through dysregulation of the peripheral immune system. Knowledge gained through this workflow unravels putative hallmark biological targets and mediators of drug-induced mood and cognitive disorders that need to be further assessed and validated in experimental models. Thereafter, they can be used to substantially improve in silico/in vitro/in vivo tools for predicting these adversities at a preclinical stage.

1 December 2011 in Drug Discovery Today: Therapeutic Strategies
Verified
Journal Article
Closed access
ELEftychia Lekka
Eftychia Lekka
SDSpyros N. Deftereos
Spyros N. Deftereos
APAris Persidis
Aris Persidis
APAndreas Persidis
Andreas Persidis
CAChristos Andronis
Christos Andronis